Therapeutic gene targeting approaches for the treatment of dyslipidemias and atherosclerosis

Mäkinen, Petri; Ylä‐Herttuala, Seppo

doi:10.1097/mol.0b013e32835da13c

Cited by 16 publications

(13 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Novel gene therapy approaches for the treatment of hyperlipidemia have been directed. New therapies for lowering lipid levels are now being tested in clinical trials, and both RNAi-based and antisense oligonucleotide therapies have revealed promising results in lower in cholesterol levels (Mäkinen & Ylä-Herttuala, 2013).…”

Section: Therapeutic Gene Targetingmentioning

confidence: 99%

Nanoparticulate carrier system: a novel treatment approach for hyperlipidemia

2014

View full text Add to dashboard Cite

Hyperlipidemia is a prevailing risk factor that leads to development and progression of atherosclerosis and consequently cardiovascular diseases. Several antihyperlipidemic drugs are having various disadvantages such as low water solubility and poor bioavailabilty due to presystemic gastrointestinal clearance. Thus, there is a considerable need for the development of efficient delivery methods and carriers. This review focuses on the importance and role of various nanoparticulate systems as carrier for antihyperlipidemic drugs in the treatment of hyperlipidemia. Some nanoparticle technology-based products are approved by FDA for effective treatment of hyperlipidemia, namely Tricor® by Abbott Laboratories (Chicago, IL, USA) and Triglide® by Skye Pharma (London, UK). Efforts to address each of these issues are going on, and should remain the focus on the future studies and look forward to many more clinical products in the future.

show abstract

Section: Therapeutic Gene Targetingmentioning

confidence: 99%

Nanoparticulate carrier system: a novel treatment approach for hyperlipidemia

2014

View full text Add to dashboard Cite

show abstract

“…Antisense and RNA interference (RNAi) technology are most commonly used strategies to eliminate or silence the expression of target genes [66]. These technologies are also used as a tool to study gene function in cancer cells [67].…”

Section: Gene Targetingmentioning

confidence: 99%

HMGB1: A Promising Therapeutic Target for Prostate Cancer

et al. 2013

View full text Add to dashboard Cite

High mobility group box 1 (HMGB1) was originally discovered as a chromatin-binding protein several decades ago. It is now increasingly evident that HMGB1 plays a major role in several disease conditions such as atherosclerosis, diabetes, arthritis, sepsis, and cancer. It is intriguing how deregulation of HMGB1 can result in a myriad of disease conditions. Interestingly, HMGB1 is involved in cell proliferation, angiogenesis, and metastasis during cancer progression. Furthermore, HMGB1 has been demonstrated to exert intracellular and extracellular functions, activating key oncogenic signaling pathways. This paper focuses on the role of HMGB1 in prostate cancer development and highlights the potential of HMGB1 to serve as a key target for prostate cancer treatment.

show abstract

“…According to unpublished reports, the drug decreased apoC-III levels up to 78% in a Phase I study of 32 subjects and is currently undergoing a Phase II trial [203,204]. Similar gene silencing approaches have been carried out through the use of antisense oligonucleotides and RNAi directed against apoB-100 and PCSK9, as have been reviewed elsewhere [132]. …”

Section: Apoc-iiimentioning

confidence: 99%

Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics

Larach

Cuchel

Rader

2013

Clinical Lipidology

View full text Add to dashboard Cite

Identification of the CETP, LIPG (encoding endothelial lipase) and APOC3 genes, and ana lysis of rare genetic variants in them, have allowed researchers to increase understanding of HDL metabolism significantly. However, development of cardiovascular risk-reducing therapeutics targeting the proteins encoded by these genes has been less straightforward. The failure of two CETP inhibitors is complex but illustrates a possible over-reliance on HDL cholesterol as a marker of therapeutic efficacy. The case of endothelial lipase exemplifies the importance of utilizing population-wide genetic studies of rare variants in potential therapeutic targets to gain information on cardiovascular disease end points. Similar population-wide studies of cardiovascular end points make apoC-III a potentially attractive target for lipid-related drug discovery. These three cases illustrate the positives and negatives of single-gene studies relating to HDL-related cardiovascular drug discovery; such studies should focus not only on HDL cholesterol and other components of the lipid profile, but also on the effect genetic variants have on cardiovascular end points.

show abstract

Therapeutic gene targeting approaches for the treatment of dyslipidemias and atherosclerosis

Cited by 16 publications

References 70 publications

Nanoparticulate carrier system: a novel treatment approach for hyperlipidemia

Nanoparticulate carrier system: a novel treatment approach for hyperlipidemia

HMGB1: A Promising Therapeutic Target for Prostate Cancer

Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics

Contact Info

Product

Resources

About